Share and Follow
In a recent development from New Jersey, a pharmaceutical company has initiated a voluntary recall of thousands of bottles containing a combination medication for high blood pressure. This decision comes amid concerns over potential cross-contamination with another pharmaceutical product, as reported by the Food and Drug Administration (FDA).
The recall specifically affects over 11,100 bottles of tablets combining bisoprolol fumarate and hydrochlorothiazide, which are marketed under the brand name Ziac. During routine testing, reserve samples revealed the unexpected presence of ezetimibe, a medication typically prescribed for managing high cholesterol levels, according to an online report by FDA officials.
Updated:
(NewsNation) — A New Jersey drug maker has voluntarily recalled thousands of bottles of a combination high blood pressure medication over concerns the product could be cross-contaminated with another drug, the Federal Drug Administration says.
The recall covers more than 11,100 bottles of bisoprolol fumarate and hydrochlorothiazide tablets under the brand name Ziac. Testing of reserve samples showed presence of ezetimibe, a drug used for high cholesterol, FDA officials said in a report published online.
The recall level for the drug is Class III, meaning the use or exposure to the product is “not likely to cause adverse health consequences.”
Glenmark Pharmaceuticals Inc., located in Elmwood Park, is recalling the pills, which are in 2.5 mg and 6.25 mg doses.
The FDA says packages affected are:
- 30-count bottles NDC 68462-878-30
- 100-count bottle NDC-68462-878-01
- 500-count bottles NDC68462-878-05
The affected lot numbers were set to expire beginning in November 2025 through May 2026.
